Andreas Maetzel
Division of Clinical Decision Making and Health Care Research
University Health Network Research Institute
Toronto
Ontario
Canada
Name/email consistency: high
- The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Maetzel, A., Li, L.C., Pencharz, J., Tomlinson, G., Bombardier, C. Ann. Rheum. Dis. (2004)
- Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Maetzel, A., Ruof, J., Covington, M., Wolf, A. Pharmacoeconomics (2003)
- Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion. Maetzel, A. Can. J. Gastroenterol. (2003)
- The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel, A., Krahn, M., Naglie, G. Arthritis Rheum. (2003)
- Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial. Maetzel, A., Strand, V., Tugwell, P., Wells, G., Bombardier, C. Pharmacoeconomics (2002)
- The economic burden of low back pain: a review of studies published between 1996 and 2001. Maetzel, A., Li, L. Best. Pract. Res. Clin. Rheumatol (2002)
- Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Maetzel, A., Strand, V., Tugwell, P., Wells, G., Bombardier, C. Arthritis Rheum. (2002)